Association between Bone Marrow Mesenchymal Stem Cell Characterizations and the Administration of Antiarrhythmic Drugs in Patients with Severe Left Ventricular Dysfunction after Off-Pump Bypass Surgery
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-5 (e2)
https://doi.org/10.22037/amls.v6.31297
Abstract
Background and Aim: Atrial fibrillation is the most common arrhythmia after coronary artery bypass grafting (CABG) and occurs in up to 30% of patients with heart failure. Mesenchymal stem cells (MSCs) can regenerate and improve cardiac function after tissue damage and are used in clinical trials. Due to the possible ability of MSCs to improve cardiac functions, in this work, we aimed to examine the probable association of the MSCs proliferation rate with the requirement for antiarrhythmic drugs in patients with severe left ventricular dysfunction after off-pump CABG.
Methods: Bone marrow samples were obtained from the sternum of 30 patients who underwent off-pump CABG at Afshar Hospital and Seyed Al-Shohada Hospital. For calculating MSCs doubling time, the cells were counted after 4, 7, and 14 days using trypan-blue color and a hemocytometer.
Results: There were no significant differences between MSCs' doubling time and the patient's age and gender. The percentage of women patients who require antiarrhythmic medicine was significantly higher than men after surgery. Also, we demonstrated that the BMSCs doubling time in female patients who received antiarrhythmic drugs was less than that of male patients who received antiarrhythmic drugs, but these differences were not significant.
Conclusion: Based on this research, we concluded that women patients who received antiarrhythmic drugs were significantly higher than men, but there was no apparent relevancy between MSCs doubling time and antiarrhythmic drugs requirement in patients with severe left ventricular dysfunction.
*Corresponding Author: Zakieh Sadat Sheikhalishahi; Email: z.sheikhalishahi@gmail.com
Please cite this article as: Esmailidehaj M, Mirhosseini SJ, Sheikhalishahi ZS. Association between Bone Marrow Mesenchymal Stem Cell Characterizations and the Administration of Antiarrhythmic Drugs in Patients with Severe Left Ventricular Dysfunction after Off-Pump Bypass Surgery. Arch Med Lab Sci. 2020;6:1-5 (e2). https://doi.org/10.22037/amls.v6.31297
- Severe Left Ventricular Dysfunction
- Antiarrhythmic Drug
- Mesenchymal Stem Cell
- Doubling Time
How to Cite
References
Savarese G, Lund LH. Global public health burden of heart failure. Cardiac failure review. 2017;3(1):7.
Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507.
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology. 2014;11(11):639.
Simmers MB, Cole BK, Ogletree ML, Chen Z, Xu Y, Kong L-j, et al. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells. Thrombosis research. 2016;143:34-9.
Erdil N, Gedik E, Donmez K, Erdil F, Aldemir M, Battaloglu B, et al. Predictors of postoperative atrial fibrillation after on-pump coronary artery bypass grafting: is duration of mechanical ventilation time a risk factor? Annals of Thoracic and Cardiovascular Surgery. 2014;20(2):135-42.
Laksman Z, Wauchop M, Lin E, Protze S, Lee J, Yang W, et al. Modeling atrial fibrillation using human embryonic stem cell-derived atrial tissue. Scientific reports. 2017;7(1):1-11.
Fisher SA, Doree C, Mathur A, Taggart DP, Martin‐Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016(12).
Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2019:1-7.
Caplan AI. Mesenchymal stem cells: time to change the name! Stem cells translational medicine. 2017;6(6):1445-51.
Shafaei Z, Abazari O, Divsalar A, Ghalandari B, Poursoleiman A, Saboury AA, et al. Effect of a Synthesized Amyl-Glycine1, 10-Phenanthroline Platinum Nitrate on Structure and Stability of Human Blood Carrier Protein, Albumin: Spectroscopic and Modeling Approaches. Journal of fluorescence. 2017;27(5):1829-38.
Guo X, Bai Y, Zhang L, Zhang B, Zagidullin N, Carvalho K, et al. Cardiomyocyte differentiation of mesenchymal stem cells from bone marrow: new regulators and its implications. Stem cell research & therapy. 2018;9(1):44.
Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2020;38(2):609-15.
Ward MR, Abadeh A, Connelly KA. Concise review: rational use of mesenchymal stem cells in the treatment of ischemic heart disease. Stem cells translational medicine. 2018;7(7):543-50.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. The Lancet. 2019;393(10175):1034-44.
Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a new designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. Journal of Biomolecular Structure and Dynamics. 2016;34(5):1123-31.
Smith ED, Tome J, Mcgrath R, Kumar S, Concannon M, Day SM, et al. Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. International journal of cardiology. 2019;274:226-31.
Hemmeryckx B, Feng Y, Frederix L, Lox M, Trenson S, Vreeken R, et al. Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction. European journal of pharmacology. 2018;832:145-55.
Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro‐inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. Iranian Journal of Allergy, Asthma and Immunology. 2019:1-10.
Yu H, Zhang N, Zhu J, Ma Q, Zhao Y, Wang Y, et al. Exosomes derived from human umbilical cord MSCs rejuvenate aged MSCs and enhance their functions for myocardial repair. 2020.
Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA, et al. Interaction of the synthesized anticancer compound of the methyl-glycine 1, 10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking. Journal of the Iranian Chemical Society. 2020:1-14.
Wang D, Zhang F, Shen W, Chen M, Yang B, Zhang Y, et al. Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. International journal of cardiology. 2011;152(3):314-20.
Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. 2009;54(24):2277-86.
Mills WR, Mal N, Kiedrowski MJ, Unger R, Forudi F, Popovic ZB, et al. Stem cell therapy enhances electrical viability in myocardial infarction. Journal of molecular and cellular cardiology. 2007;42(2):304-14.
Abbasi M, Abazari OO. Probing the Biological evaluations of a new designed Palladium (II) complex using spectroscopic and theoretical approaches: Human Hemoglobin as a Target. Archives of Medical Laboratory Sciences. 2018;3(3).
Lin H, Sohn J, Shen H, Langhans MT, Tuan RS. Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing. Biomaterials. 2019;203:96-110.
Asumda FZ, Chase PB. Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC cell biology. 2011;12(1):44.
- Abstract Viewed: 98 times
- PDF Downloaded: 75 times